

Express Mail No. EL651891515US

FORM PTO-1390 (REV 10-95)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				15675P368	
				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/890841	
INTERNATIONAL APPLICATION NO PCT/FR00/00241		INTERNATIONAL FILING DATE February 2, 2000		PRIORITY DATE CLAIMED February 3, 1999	
TITLE OF INVENTION METHOD FOR DETECTING BACTERIA CULTIVATED IN ANAEROBIC CONDITION					
APPLICANT(S) FOR DO/EO/US Alain Rambach; Christine Favier					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b)) and PCT articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4))</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5))</p> <p>Items 11. to 16. below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment</p> <p>14. <input type="checkbox"/> A subsequent specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input checked="" type="checkbox"/> Other items or information:</p> <p>priority request; preliminary exam report w/o amendments; English translation of prelim. exam. report; request of filing; forms pct/ib 301 & 304</p>					

JC05 Rec'd PCT/PTO 02 AUG 2007

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
		PCT/FR00/00241		15675P368	

17. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482 nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by EPO or JPO **\$1000.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO. . . . **\$860.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee paid to USPTO (37 CFR 1.445(a)(2)) **\$700.00**

International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$690.00**

International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) **\$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	27 - 20 =	7	X \$18.00
Independent claims	4 - 3 =	1	X \$78.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00
TOTAL OF ABOVE CALCULATIONS =			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			
SUBTOTAL =			
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			
TOTAL NATIONAL FEE =			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property			
TOTAL FEES ENCLOSED =			

CALCULATIONS FOR PTO USE ONLY

\$	860.00
\$	
\$	126.00
\$	78.00
\$	270.00
\$	1334.00
\$	
\$	1334.00
\$	
\$	1334.00
\$	
\$	1334.00
\$	Amount to be: refunded
\$	charged

a. ☒ A check in the amount of \$ 1334.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 022666. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Blakely, Sokoloff, Taylor & Zafman LLP
 12400 Wilshire Blvd. 7th Floor
 Los Angeles, CA 90025-1026

 SIGNATURE

Eric S. Hyman
 NAME

30,139
 REGISTRATION NUMBER

[illegible]

15

20

25

35

fragilis. No potentially pathogenic strain has been able to be distinguished as being distinct.

5 The study of a plasma glycoprotein secreted in stools,
the α -1-proteinase inhibitor, has demonstrated an
impairment in the bacterial metabolism in patients
suffering from CD. Indeed, in healthy subjects, this
glycoprotein is deglycosylated along the whole length
10 of the colon following the action of exoglycosidases of
bacterial origin. On the other hand, in patients, it
remains glycosylated, which results in a defect in the
activity of these osidases. This defect has indeed been
proven by assays of glycosidase activities in fecal
extracts. The enzymatic activities, and in particular
15 that of β -galactosidase, were found to be considerably
reduced in the patients compared with the controls,
Favier et al., (1996), Differentiation and
identification of human fecal anaerobic bacteria
producing β -galactosidase (a new methodology), Journal
20 of Microbiological Methods 27, 25-31; Favier et al.,
(1997), Fecal β -D-galactosidase Production and
Bifidobacteria Are Decreased in Crohn's Disease,
Digestive Diseases and Sciences, 42, 817-822.

25 The capacity of the fecal flora in these patients and
in healthy subjects, incubated under appropriate
conditions, to produce and to liberate β -galactosidase,
was studied. To do this, fecal samples are cultured,
under an anaerobic atmosphere and at 37°C, in a Wilkins
30 Chalgren (WC) broth supplemented with pig gastric
mucins (in order to promote the growth of
microorganisms and the production of exoglycosidases).
The β -galactosidase activity is added on the
supernatants of aliquots collected at the beginning
35 (2 h) and at the end (22 h) of incubation.

Thus, a methodology which makes it possible to
selectively count the anaerobic microorganisms
releasing β -galactosidase in the feces was developed.

However, given the complexity of the flora, the conventionally used methods, which consist in isolating the colonies, identifying the microorganisms and then assaying the enzymatic activity which they produce do not appear to be capable of responding to the problem posed.

Recently, the use of chromogenic substrates such as 5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside or X-gal, has allowed the detection of Lac⁺ anaerobic microorganisms. Following enzymatic hydrolysis, the substrate undergoes oxidative polymerization which causes the formation of a blue precipitate. This methodology, which makes it possible to differentiate, directly on a Petri dish, the microorganisms capable of releasing β -gal in the medium, was applied to the study of fecal microorganisms in patients and healthy subjects. The results obtained were compared with those from the analysis, with the aid of selective media, of the principal groups of microorganisms known for their capacity to produce β -galactosidase. *Bacteroides*, *Lactobacillus* and *Bifidobacterium*.

Examples of such media are presented in Chevalier, P., Roy, D. and Savoie, L., (1991) X-Gal based medium for simultaneous enumeration of bifidobacteria and lactic acid bacteria in milk, J. Microbiol. Methods 13, 75-83; and in Livingston SJ, Kominos SD, Lee RB, (1978), New medium for selection and presumptive identification of the *Bacteroides fragilis* group, J. Clin, Microbiol 7, 448-453.

However, it is sometimes difficult to visualize the bacteria. There has been developed, in the context of the present invention, a medium containing an oxidizing metal complex which makes it possible in particular to intensify the halos of colors obtained around the colonies. This improvement in the technique mentioned above has been achieved so as to promote the oxidative reaction of the substrate in the reduced medium

necessary for the growth of bacteria under anaerobic conditions.

Thus, no prior art document describes or suggests the present invention as defined hereinafter.

DESCRIPTION

The present invention relates to a bacterial culture medium, for use under anaerobic conditions, comprising at least one metal complex which allows the oxidative polymerization of an indoxyl derivative and a substrate containing an indoxyl derivative resulting in an insoluble colored compound. Said metal complex, in particular ammoniacal iron citrate, has a concentration of between 0.3 and 0.9 mg/ml, preferably 0.6 mg/ml. The culture medium according to the invention may comprise at least one selected from X-Gal, X-Phos, X-acglmn, Mag-Gal, Mag- α -Gal, and Mag-Phos, preferably X-Gal, at a concentration of between 10 and 500 mg/l, particularly between 50 and 200 mg/l, preferably at 100 mg/ml.

The expression "bacterium" in the context of the invention is understood to mean anaerobic bacteria, aerobic anaerobic bacteria, and any bacterium producing, naturally or otherwise, a β -galactosidase. Among the transformed bacteria, there may be mentioned in particular a bacterium transformed by a plasmid containing the LacZ gene, optionally under the control of a promoter of interest.

Consequently, the medium according to the invention is intended for the detection of anaerobic bacteria, aerobic anaerobic bacteria and any bacterium producing a β -galactosidase.

There may be mentioned, by way of example, bacteria of the genus *Bifidobacterium*, *Clostridium*, *Citrobacter*,

Escherichia, and/or *Bacteroides*, in particular of the strains *Bifidobacterium bifidum*, *Clostridium perfringens*, *Clostridium butyricum*, *E. coli*, and/or *Bacteroides fragilis*.

5

Preferably, this culture medium comprises cysteinated Columbia medium well known to a person skilled in the art, whose ingredients and characteristics are the following (as a base qsp according to the
10 manufacturer):

Glucose	5 g
Cysteine hydrochlorate	0.3 g
Agar	5 g
Water	1000 ml
PH	7.3
Autoclaving	15 mm, 120°C

However, the medium according to the invention is not limited to a list of particular ingredients, such that
15 it can be adapted to the culture of a given bacterium which it is sought to detect. For example, the TSC medium, described below, can serve as a base for the preparation of the medium according to the invention.

TSC medium (base qsp according to the manufacturer):

Tryptose	15 g
Soya bean flour peptone	5 g
Yeast extract	5 g
Sodium disulfite	1 g
Agar	15 g
Water	1000 ml

20

The culture medium according to the invention may contain, in addition, magnesium sulfate at a concentration of between 5 mM and 100 mM, preferably 20 mM, and/or at least one antibiotic, for example
25 cycloserine, preferably at 0.4 g/l, neomycin supplemented with polymyxin, preferably at 0.02 g/l and 0.05 g/l respectively.

An additional aspect of the present invention relates to a combination product comprising at least one oxidizing metal complex and at least one substrate containing an indoxyl derivative resulting in an insoluble colored compound for use simultaneously, separately or spread out over time, intended for the detection of bacteria. Said substrate may be selected from X-Gal, X-Phos, X-acglmn, Mag-Gal, Mag- α -Gal, and Mag-Phos, preferably X-Gal, and said metal complex is ammoniacal iron citrate.

This combination product is characterized in that the metal complex and the substrate are carried in an aqueous solvent at a concentration of between 3 and 900 mg/ml, preferably at 60 mg/ml, or an organic solvent at a concentration of between 100 mg/l and 50 g/l, particularly between 500 mg/l and 20 g/l, preferably at 10 g/l. The combination product according to the invention may contain, in addition, magnesium sulfate at a concentration of between 50 mM and 10 M, preferably 2 M, and/or at least one antibiotic.

The subject of an advantageous aspect of the present invention is a bacterial detection kit comprising a combination product as defined above.

In the context of the invention, the term "detection" is understood to mean the visualization, optionally the identification, and the quantification of bacteria.

The present invention also relates to a method for the detection of bacteria, characterized in that it comprises the following steps:

- a) there are added to a medium which may contain said bacteria, cultured under anaerobic conditions, at least one substrate containing an indoxyl derivative resulting in an insoluble colored compound,
- b) at least one oxidizing metal complex, in particular ammoniacal iron citrate, is added,

- c) the appearance of a colored precipitate around the colonies (halo) and/or a color of the colonies is visualized.
- 5 In another embodiment, the method for the detection of bacteria comprises the following steps:
- a) said bacteria are cultured in a medium according to the invention under anaerobic conditions,
- b) the appearance of a colored precipitate around the colonies (halo) and/or a color of the colonies is visualized;
- 10 or alternatively the following steps:
- a) a combination product according to the invention is added to a medium which may contain said bacteria cultured under anaerobic conditions,
- 15 b) the appearance of a colored precipitate around the colonies (halo) and/or a color of the colonies is visualized.
- 20 An additional aspect of the present invention relates to the use of an oxidizing metal complex, preferably ammoniacal iron citrate, for catalyzing the oxidative polymerization of indoxyl derivatives resulting in an insoluble colored compound, in particular for improving
- 25 the detection of the release of an indoxyl derivative by an enzyme from a substrate containing an indoxyl derivative, it being possible for said substrate to be a substrate selected from X-Gal, X-Phos, X-acglmn, Mag-Gal, Mag- α -Gal, and Mag-Phos, preferably X-Gal. Said
- 30 metal complex makes it possible to intensify the colored halo and/or to increase the color of the colonies. Indeed, it reacts with the indoxyl derivative according to the invention to give a colored compound which precipitates.
- 35 The invention also relates to the use of a medium, of a combination product or of a kit as described above for the detection of bacteria which possess an enzyme allowing the release of an indoxyl derivative from a substrate containing an indoxyl derivative.

The addition of ammoniacal iron citrate makes it possible, not only to visualize colors which do not appear in culture in jars under anaerobic conditions, but also to intensify the halo of colors of the colonies cultured under a plastic bag under anaerobic conditions. The columbia medium appears to be completely advantageous for the appearance of the colors. Of course, the colors and the intensity of the colors obtained depend on their strains, the level of expression and of secretion of β -galactosidase.

The examples below are given to illustrate the present invention but they do not limit the modalities of implementation thereof.

EXAMPLE 1: MEDIUM INTENDED FOR THE DETECTION OF BIFIDOBACTERIA

The capacity of ammoniacal iron citrate (AIC) to increase the formation of indigo in a Generbag Anaer[®] bag and in a jar was determined.

A strain of *Bifidobacterium bifidum* was inoculated into the cysteinated Columbia medium + X-Gal with or without AIC (0.3 g/l), and then the effect of the addition of AIC was tested before or after autoclaving/regeneration.

The colonies in the Generbag Anaer[®] bag are surrounded by a halo which is more intense in the presence of AIC, and the halos became visible in a jar.

The bacterial count shows a reduction in the number of microorganisms when AIC is added to the medium after autoclaving/regeneration.

Thus, AIC, added before regeneration of the bottle, promotes the appearance of the halo. Various concentrations of AIC were then tested on three

Bifidobacterium strains. The results are presented in table I below.

Table I

AIC (g/l)	0	0.3	0.6	0.9
<i>B. bifidum</i>	Ø	+	++	+++↓
<i>B. longum</i>	Ø	+	++	++
<i>B. dentium</i>	Ø	+	++	++

Ø: without halo

+ → +++: intensity of the halo

↓: reduction in the microorganisms (here by 90%)

Consequently, 0.6 g/l of AIC appears to be an ideal concentration for visualizing the presence of a halo around the *Bifidobacterium* colonies after culturing in a jar.

EXAMPLE 2: STUDY OF VARIOUS SUBSTRATES IN ORDER TO CAUSE THE COLOR TO APPEAR UNDER ANAEROBIC CONDITIONS BY ADDITION OF AIC

Various substrates were tested (100 mg/l) in cysteinated Columbia medium, in the presence and in the absence of AIC (0.6 g/l).

2.1 Medium supplemented with X-Gal

The presence of AIC made it possible to observe the color due to the hydrolysis of the X-Gal substrate for the *Clostridium* colonies:

The colonies of *C. perfringens* (β -galactosidase+) are other without AIC; green-blue with a blue halo in the presence of AIC. The colonies of *C. butyricum* (β -galactosidase+) are cream-colored without AIC; greenish cream-colored surrounded by a slight green-blue halo with AIC. On the other hand, the colonies of *Citrobacter* (β -galactosidase+) remain cream-colored with or without AIC: either the AIC is not sufficient in order to see the color, or the microorganisms did

not hydrolyze the substrate. In this strain, the LacZ gene is undoubtedly under the control of the lactose operon. Consequently, it is necessary to add lactose to the culture medium in order to induce the expression of β -galactosidase.

The differences between the medium with AIC and the medium without the AIC are particularly great for the strains of *C. perfringens* and *C. butyricum*.

2.2 Medium supplemented with Mag-Gal

The colonies of *C. perfringens* (β -galactosidase+) are ocher without AIC; pink with a pink halo in the presence of AIC.

The colonies of *C. butyricum* (β -galactosidase+) are cream-colored without AIC; pink with a pink halo with AIC, and those of *Citrobacter* (β -galactosidase+) are cream-colored without AIC; pink with AIC. The presence of AIC made it possible to observe the coloring due to the hydrolysis of the Mag-Gal substrate for the colonies of *Clostridium butyricum* and for *Citrobacter*. The enzymes of the latter would therefore not be inducible but would be more capable of hydrolzing Mag-Gal than X-Gal.

The differences between the medium with AIC and the medium without AIC are, in order, greatly marked for the strain of: *C. perfringens*, *C. butyricum*, *Citrobacter*.

2.3 Medium supplemented with X-Phos

5 The colonies of *C. perfringens* (alkaline phosphatase+) are cream-colored without AIC; greenish cream-colored with a slight blue halo in the presence of AIC.

10 The colonies of *C. butyricum* (alkaline phosphatase-) are cream-colored without AIC; cream-colored with a very light halo near the colony and then blue at the periphery with AIC, and those of *Citrobacter* are cream-colored without AIC, green-blue with a light blue-green halo with AIC.

15 The colonies of *E. coli* are very light greenish cream-colored without AIC and darker with AIC. Finally, those of *Bacteroides fragilis* (alkaline phosphatase+) are cream-colored when they are isolated, blue in group without AIC; deep cream-colored, light brown with AIC.

20 The differences between the medium with AIC and the medium without AIC are very marked for the strain of: *Citrobacter*, then there are in order: *C. butyricum*, *C. perfringens*, *E. coli* and finally *B. fragilis*. Even if the colors are not sharp, the presence of AIC made it possible to observe the color (*C. perfringens*, *C. butyricum*), or to increase the color (*E. coli*) due to
25 the hydrolysis of the X-Phos substrate. As regards *B. fragilis*, this releases the extra cellular enzymes which form halos of undefinable colors.

2.4 Medium supplemented with Mag-Phos

30 The colonies of *C. perfringens* (alkaline phosphatase+) are cream-colored without AIC; pink with a pink halo in the presence of AIC. Those of *C. butyricum* (alkaline phosphatase-) are cream-colored without AIC; pink with
35 a pink halo with AIC. Those of *Citrobacter* are cream-colored (darker center) without AIC; pink (pink agar) with AIC.

Those of *E. coli* are cream-colored (darker center) without AIC; pink (pink agar) with AIC. That of *Bacteroides fragilis* are cream-pink without AIC; cream-pink with a brownish halo with AIC.

- 5 The presence of AIC made it possible to observe the color due to the hydrolysis of the Mag-Phos substrate for the colonies of *Clostridium*, *E. coli* and *Citrobacter*.

10 The differences between the medium with AIC and the medium without AIC are more marked for the strains of: *C. perfringens* and *C. butyricum*, then there are *Citrobacter* and *E. coli*, and finally *B. fragilis*.

2.5 Medium supplemented with Mag- α -Gal

- 15 The colonies of *C. perfringens* (Mag- α -Gal+) are cream-colored without AIC; pink in the presence of AIC. Those of *Bacteroides fragilis* (Mag- α -Gal+) are dark cream-colored without AIC; cream-pink with AIC. Those of *C. butyricum* (Mag- α -Gal+), *Citrobacter* and *E. coli* are cream-colored without AIC; darker or light cream-colored with AIC.

20 The differences between the medium with AIC and the medium without AIC are more marked for the strains of:
25 *C. perfringens* and *B. fragilis*, then there are *C. butyricum*, *Citrobacter* and *E. coli*.

2.6 Medium supplemented with X-acglmn

- 30 The colonies of *C. perfringens* (X-acglmn+) are cream-colored without AIC; very slightly greenish cream-colored in the presence of AIC. Those of *C. butyricum* (X-acglmn-) do not exhibit growth without AIC; are greenish with a blue halo in the presence of AIC.
35 *Bacteroides fragilis* (X-acglmn+), *Citrobacter* and *E. coli* are cream-colored with or without AIC.

The differences between the medium with AIC and the medium without AIC are more marked for the strains of: *C. perfringens*.

- 5 In conclusion, it is evident from these studies that the colors appeared in a medium supplemented with AIC, for the majority of the colonies. *C. butyricum* gives results which contradict its presumed enzymatic activities; however, the strain used is not necessarily
10 represented here of the species.

EXAMPLE 3: EXPERIMENTS IN "NORMAL" TSC MEDIUM

- 15 To be as close as possible to the selective media allowing enumeration of *Clostridii*, a first study was carried out in "normal" basic TSC medium with disulfite and AIC (1.0 g/l), and without antibiotics.

- 20 The colonies of *Clostridium perfringens* are black. Whether X-Gal, Mag-Phos, X-glu or X-glucu is added, the colors due to the hydrolysis of these substrates remain difficult to see. Nevertheless, the blue-gray halos around the colonies of *C. perfringens* in the presence of X-Gal (100 mg/l, combined with Mag-Phos 50 m/l or
25 with X-glucu 100 m/l) can make it possible to distinguish between the *C. perfringens* and the other microorganisms. These halos are also observed around colonies of *E. coli* which are all blue (solely as X-Gal+ Mag-Phos).

- 30 Thus, the appearance of the color is impeded by the use of disulfites by *C. perfringens*. It appears necessary to work in a medium without disulfite.

35 EXAMPLE 4: EXPERIMENTS IN TSC MEDIUM WITHOUT DISULFITE

The substrates X-Gal, Mag-Gal, X-Phos and Mag-Phos (100 mg/l) were tested in the presence and in the absence of AIC (0.6 g/l) by reusing the base of the TSC

With X-Gal, the differences between the medium with AIC and the medium without AIC are more marked for the strains of: *C. perfringens* and *E. coli*, and then *Citrobacter* and *B. fragilis*. *C. butyricum* remains cream-colored with AIC.

With X-Phos, the differences between the medium with
15 AIC and the medium without AIC are more marked for the
strain of: *E. coli*, *Citrobacter* and then those of *C.*
perfringens and *B. fragilis*. *C. butyricum* did not grow
in the absence of AIC.

25 In conclusion, it is preferable to use the cysteinated Columbia medium to cause a more intense color to appear compared with the TSC medium.

If a value is given for the intensity of the colors of the colonies according to the substrate, β -galactosidase appears to make it possible to visualize better *C. perfringens* compared with phosphatase (see table II below)

Table II

	<i>C.perfringens</i>	<i>C.butyricum</i>	<i>Citrobacter</i>	<i>E. coli</i>	<i>B.fragilis</i>
X-Gal	3	2	0	Ø	Ø
X-Gal TSC	3	0	2	3	2
Mag-Gal	3	2	1	Ø	Ø
Mag-Gal TSC	3	Ø	2	2	1
GALACT- OSIDASE	3	1.33	1.25	2.5	1.5
X-Phos	2	2	3	2	1
X-Phos TSC	2	Ø	3	3	2
Mag-Phos	3	3	2	2	1
Mag-Phos TSC	2	0	3	3	0
PHOSPHATASE	2.25	1.66	2.75	2.5	1

Ø: lack of data

3 to 0: relative intensity of the color of the colonies
for a given medium with a given substrate

EXAMPLE 5: STUDY OF THE EFFICACY OF THE ADDITION OF FERRICYANIDES TO CAUSE THE COLOR TO APPEAR UNDER ANAEROBIC CONDITIONS

Ferricyanide was used alone at 0.6 g/l. There is no
difference between the media containing these products
or otherwise for the substrate X-Gal.

Only the colonies of *Bacteroides fragilis* are blue with
X-Phos in the presence of ferricyanide.

Thus, X-phos + ferricyanide may be an excellent medium
for preidentifying *Bacteroides*.

EXAMPLE 6: IMPROVEMENT OF THE MEDIUM INTENDED FOR THE STUDY OF CLOSTRIDIUM BY ADDITION OF ANTIBIOTICS

To resemble the TSC medium for selecting *C.*
perfringens, antibiotics were added to the TSC base:

- either cycloserine (0.4 g/l);

- or neomycin supplemented with polymyxin (0.02 and 0.05 g/l respectively);
- or the three together.

5 All the colonies (*C. perfringens*, *C. butyricum*, *E. coli*, *B. fragilis*, *Citrobacter*) grow in the presence of cycloserine alone. On the other hand, the combination neomycin and polymyxin (0.02 g/l and 0.05 g/l) makes it possible to inhibit the growth of *B. fragilis*, *E. Coli*
10 and *Citrobacter*.

The following two strains of *Clostridium* grow:

- the colonies of *C. butyricum* remain cream-colored,
- those of *C. perfringens* are slightly colored
15 (colonies having a pink center with Mag-Gal (100 mg/l) and AIC (0.6 g/l) and colonies having a greenish center surrounded by a very slight halo with X-Gal (100 mg/l) and AIC (0.6 g/l)).

20 In cysteinated Columbia medium, the colors ought to be darker and the addition of antibiotics, which possess the great advantage of being autoclavable, ought to make it possible to inhibit the other microorganisms.

25 The growth of *C. butyricum* is not disruptive in TSC medium given that the colonies remain cream-colored, but will be disruptive in Columbia medium because the colonies have colors close to those of *C. perfringens*.

0990844-030304

CLAIMS

1. A bacterial culture medium, for use under anaerobic conditions, comprising at least one metal complex which allows the oxidative polymerization of an indoxyl derivative and a substrate containing an indoxyl derivative resulting in an insoluble colored compound.
2. The culture medium as claimed in claim 1, in which said metal complex has a concentration of between 0.3 and 0.9 mg/ml, preferably 0.6 mg/ml.
3. The culture medium as claimed in either of claims 1 and 2, in which said metal complex is ammoniacal iron citrate.
4. The culture medium as claimed in claim 1, in which said substrate is selected from X-Gal, X-Phos, X-acglmn, Mag-Gal, Mag- α -Gal, and Mal-Phos, preferably X-Gal.
5. The culture medium as claimed in claim 4, in which said substrate has a concentration of between 10 and 500 mg/l, particularly between 50 and 200 mg/l, preferably at 100 mg/ml.
6. The culture medium as claimed in one of claims 1 to 5, characterized in that it is intended for the detection of anaerobic bacteria, aerobic anaerobic bacteria and any bacterium producing a β -galatosidase.
7. The culture medium as claimed in claim 6, characterized in that it is intended for culturing bacteria of the genus *Bifidobacterium*, *Clostridium*, *Citrobacter*, *Escherichia*, and/or *Bacteroides*, in particular of the strains

Bifidobacterium bifidum, *Clostridium perfringens*,
Clostridium butyricum, *E. coli*, and/or *Bacteroides*
fragilis.

- 5 8. The culture medium as claimed in claim 7,
characterized in that it comprises cysteinated
Columbia medium.
- 10 9. The culture medium as claimed in one of claims 1
to 8, characterized in that it comprises, in
addition, magnesium sulfate at a concentration of
between 5 mM and 100 mM, preferably 20 mM, and/or
at least one antibiotic.
- 15 10. A combination product comprising at least one
oxidizing metal complex and at least one substrate
containing an indoxyl derivative resulting in an
insoluble colored compound for use simultaneously,
separately or spread out over time, intended for
20 the detection of bacteria.
- 25 11. The combination product as claimed in claim 10,
characterized in that said substrate is selected
from X-Gal, X-Phos, X-acglmn, Mag-Gal, Mag- α -Gal,
and Mag-Phos, preferably X-Gal.
- 30 12. The combination product as claimed in either of
claims 10 and 11, characterized in that said metal
complex is ammoniacal iron citrate.
- 35 13. The combination product as claimed in one of
claims 10 to 12, characterized in that said metal
complex and said substrate are carried in an
aqueous solvent at a concentration of between 3
and 900 mg/ml, preferably at 60 mg/ml, or an
organic solvent at a concentration of between
100 mg/l and 50 g/l, particularly between 500 mg/l
and 20 g/l, preferably at 10 g/l.

14. The combination product as claimed in one of
claims 10 to 13, characterized in that it
comprises, in addition, magnesium sulfate at a
concentration of between 50 mM and 10 M,
preferably 2 M, and/or at least one antibiotic.
15. A bacterial detection kit comprising a combination
product as claimed in one of claims 10 to 14.
16. A method for the detection of bacteria,
characterized in that it comprises the following
steps:
- a) there are added to a medium which may contain
said bacteria, cultured under anaerobic
conditions, at least one substrate containing
an indoxyl derivative resulting in an insoluble
colored compound,
 - b) at least one oxidizing metal complex, in
particular ammoniacal iron citrate, is added,
 - c) the appearance of a colored precipitate around
the colonies (halo) and/or a color of the
colonies is visualized.
17. The method for the detection of bacteria,
characterized in that it comprises the following
steps:
- a) said bacteria are cultured in a medium as
claimed in one of claims 1 to 9 under anaerobic
conditions,
 - b) the appearance of a colored precipitate around
the colonies (halo) and/or a color of the
colonies is visualized.
18. A method for the detection of bacteria,
characterized in that it comprises the following
steps:
- a) a combination product as claimed in one of
claims 10 to 14 is added to a medium which may

contain said bacteria cultured under anaerobic conditions,

b) the appearance of a colored precipitate around the colonies (halo) and/or a color of the colonies is visualized.

19. The use of an oxidizing metal complex for catalyzing the oxidative polymerization of indoxyl derivatives resulting in an insoluble colored compound.

20. The use as claimed in claim 19, for improving the detection of the release of an indoxyl derivative by an enzyme from a substrate containing an indoxyl derivative, it being possible for said substrate to be a substrate selected from X-Gal, X-Phos, X-acglmn, Mag-Gal, Mag- α -Gal, and Mag-Phos, preferably X-Gal.

21. The use as claimed in claim 20, for intensifying the colored halo and/or for increasing the color of the colonies.

22. The use as claimed in either of claims 20 and 21, characterized in that the oxidizing metal complex is ammoniacal iron citrate.

23. The use of a medium as claimed in one of claims 1 to 9, for the detection of bacteria which possess an enzyme allowing the release of an indoxyl derivative from a substrate containing an indoxyl derivative.

24. The use of a combination product as claimed in one of claims 10 to 14, for the detection of bacteria which possess an enzyme allowing the release of an indoxyl derivative from a substrate containing an indoxyl derivative.

Our ref.: 15675 - P368

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below, next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Method for detecting bacteria cultivated in anaerobic condition

the specification of which

is attached hereto

was filed on **February 2, 2000**

as International

Application Serial No. **PCT /FR00/00241**

And was amended on

(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I do not know and do not believe that the same was ever known or used in the United States of America before my invention thereof, or patented or described in any printed publication in any country before my invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, and that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 199, of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor(s) certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
99/01226	FRANCE	03 February 1999	XX	
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

(Application Serial No.)

PCT FR00/00241

(Filing Date)

02/02/00

(Status - patented, pending, abandoned)

Pending

(Application Serial No.)

(Filing Date)

(Status - patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status - patented, pending, abandoned)

I hereby appoint BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN, a firm including :

Keith G. Askoff, Reg. No. 33,828; Aloysius T.C. AuYeung, Reg. No. 35,432; Bradley J. Bereznak, Reg. No. 33,474; Michael A. Bernadicon, Reg. No. 35,934; Roger W. Blakely, Jr.; Reg. No. 25,831; Timothy R. Croll, Reg. No. 36,771; Daniel M. De Vos, Reg. No. 37,813; Scott A. Griffin, Reg. No. 38,167; Stephen D. Gross, Reg. No. 31,020; David R. Halvorson, Reg. No. 33,395; Michael D. Hartogs, Reg. No. 36,547; Brian D. Hickman, Reg. No. 35,894; George W. Hoover II, Reg. No. 32,992; Paul H. Hostmann, Reg. No. 36,167; Eric S. Hyman, Reg. No. 30,139; Dag H. Johansen, Reg. No. 36,172; Stephen L. King, Reg. No. 19,180; Joseph T. Lin, Reg. No. 38,225; Michael J. Mallie, Reg. No. 36,591; James D. McFarland, Reg. No. 32,544; Anthony C. Murabito, Reg. No. 35,295; Kimberley G. Nobles, Reg. No. 38,255; Ronald W. Reagin, Reg. No. 20,340; Kent R. Richardson, Reg. No. P-39,443; James H. Salter, Reg. No. 35,668; William W. Schaal, Reg. No. P-39,018; James C. Sheller, Reg. No. 31,195; Edward W. Scott IV, Reg. No. 36,000; Maria E. Sobrino, Reg. No. 31,639; Stanley W. Sokoloff, Reg. No. 25,128; Allan T. Sponseller, Reg. No. 38,318; John C. Stattler, Reg. No. 36,285; Edwin H. Taylor, Reg. No. 25,129; Lester J. Vincent, Reg. No. 31,460; Ben J. Yorks, Reg. No. 33,609; and Norman Zafman, Reg. No. 26,250; my attorneys; and William D. Davis, Reg. No. 38,428; Gary B. Goates, Reg. No. 35,159; Soyeon P. Laub, Reg. No. P-39,266; Thomas X. Li, Reg. No. 37,079; and Edwin A. Sloane, Reg. No. 34,728; my patent agents, with offices located at 12400 Wilshire Boulevard, 7th Floor, Los Angeles, California 90025, telephone (310) 207-3800, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole/First Inventor: **Alain RAMBACH**

Inventor's Signature: *Alain Rambach*

Date:

26 July 2001

Residence: **PARIS, FRANCE**

(City, State)

Citizenship: **FRANCE**

(Country)

Post Office Address: **73, Bd Montparnasse, 75006 PARIS, FRANCE**

FRX

Full Name of Second/Joint Inventor: **Christine FAVIER**

Inventor's Signature: *Christine Favier*

Date:

26 July 2001

Residence: **ALLENES-LES-MARAIS, FRANCE**

(City, State)

Citizenship: **FRANCE**

(Country)

Post Office Address: **42, rue du Cimetière, 59251 ALLENES-LES-MARAIS, FRANCE**

FRX